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Abstract 
Objective. Familial multinodular goiter (MNG), with or without ovarian Sertoli-Leydig cell tumor 
(SLCT), has been linked to DICER1 syndrome. We aimed to search for the presence of a 
germline DICER1mutation in a large family with a remarkable history of MNG and SLCT, and to 
further explore the relevance of the identified mutation. 
Design and methods. Sanger sequencing, Fluidigm Access Array and multiplex ligation-dependent 
probe amplification (MLPA) techniques were used to screen for DICER1mutations in germline DNA 
from 16 family members. Where available, tumor DNA was also studied. mRNA and protein 
extracted from carriers’ lymphocytes were used to characterize the expression of the mutant DICER1. 
Results. Nine of 16 tested individuals carried a germline, in-frame DICER1 deletion (c.4207-
41_5364+1034del), which resulted in the loss of exons 23 and 24 from the cDNA. The mutant 
transcript does not undergo nonsense-mediated decay and the protein is devoid of specific metal ion-
binding amino acids (p.E1705 and p.D1709) in the RNase IIIb domain. In addition, characteristic 
somatic ‘second hit’ mutations in this region were found on the other allele in tumors. 
Conclusions. Patients with DICER1 syndrome usually present a combination of a typically truncating 
germline DICER1mutation and a tumor-specific hotspot missense mutation within the sequence 
encoding the RNase IIIb domain. The in-frame deletion found in this family suggests that the 
germline absence of p.E1705 and p.D1709, which are crucial for RNase IIIb activity, may be enough 
to permit DICER1 syndrome to occur. 
  
Introduction 
Multinodular goiter (MNG) is a common disorder of the thyroid gland, characterized by thyroid 
enlargement due to the development of multiple hyperplastic nodules (1, 2). As opposed to toxic 
MNG, the non-toxic subtype does not result from hyperthyroidism, hypothyroidism or inflammation. 
The exact causes of MNG are not well understood. Iodine deficiency has been established as the main 
cause of endemic goiter (2, 3), whereas genetic defects may play a major role in the pathogenesis of 
sporadic and familial non-toxic MNG. Two loci have been linked to familial MNG; MNG1on 
chromosome 14q (4) and MNG2 on the X chromosome (5). In 2011, Rio Frio and coworkers (6) 
identified germline mutations in DICER1 (on chromosome 14q32) as the cause of familial MNG with 
or without ovarian Sertoli–Leydig cell tumor (SLCT) (7), adding a new phenotype to the DICER1 
syndrome (OMIM #601200). Since then, several articles have reported patients with 
germline DICER1 mutations who have MNG alone or in combination with other known DICER1-
related diseases (8, 9, 10). 
DICER1 syndrome, first identified by Hill and colleagues in 2009 (11), is a rare pediatric tumor 
predisposition syndrome caused by germline typically truncating mutations in DICER1. A spectrum 
of rare, mostly pediatric-onset tumors characterizes the syndrome, including pleuropulmonary 
blastoma, SLCT, pediatric cystic nephroma, MNG, thyroid carcinoma, and other rare sarcomas and 
dysplasias (7). Somatic missense mutations affecting the nucleotides encoding the critical metal ion-
binding residues within the catalytic RNase IIIb domain are found in the tumors (7). In the case of 
MNG, it has also been demonstrated that individual nodules may harbor distinct somatic RNase IIIb 
hotspot mutations (12, 13). 
Here, we aimed to investigate this large family with a remarkable history of MNG and SLCT for 
presence of germline and somatic DICER1 mutations and to further explore the relevance of the 
identified mutations. 
Subjects and methods 
Subjects 
The studied pedigree comprised 16 individuals from a family of Italian descent. All individuals or 
their parents gave written informed consent. The study was approved by the Institutional Review 
Board of the Faculty of Medicine of McGill University no. A12-M117-11A. All procedures were 
performed in accordance with the ethical standards of the Helsinki Declaration. 
DICER1 genetic testing 
Blood samples were obtained from all subjects and 7 formalin-fixed, paraffin-embedded (FFPE) 
tumor blocks were available from 6 individuals (n = 5 MNG, 1 SLCT, and 1 breast fibroadenoma). 
Genomic DNA was extracted from peripheral blood samples using the Gentra Puregene Blood Kit 
(QIAGEN) and from FFPE tumor tissue using the QIAamp DNA FFPE Tissue Kit (QIAGEN) 
according to the manufacturer’s instructions. 
Germline DNA from two patients was sequenced using a custom Fluidigm Access Array (14), which 
selectively targets the exons, exon–intron boundaries and 3′UTR of DICER1. In addition, multiplex 
ligation-based probe amplification (MLPA) assay was performed to screen for DICER1deletions or 
duplications (15). Long-range PCR was performed using TaKaRa LA Taq DNA Polymerase with GC 
Buffer (TaKaRa) to determine the deletion breakpoints. Primers were designed to amplify a 4801 bp 
DNA fragment of DICER1 from intron 22 to intron 24. PCR products were gel extracted using 
QIAquick Gel Extraction Kit (QIAGEN) and then, Sanger sequenced. 
The regions encoding the DICER1 RNase IIIa and IIIb domains were PCR amplified and Sanger 
sequenced in DNA extracted from the lesions to screen for hotspot mutations. 
RNA analysis and cloning assay 
Lymphoblastoid cell lines (LCLs) were established from peripheral blood lymphocytes of two 
affected individuals. LCLs from healthy, DICER1 wild-type individuals were used as controls. Total 
RNA was extracted from LCLs using TRIzol reagent (Thermo Fisher Scientific). cDNA was 
synthesized using SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific) and was 
PCR-amplified using Platinum Pfx DNA Polymerase (Thermo Fisher Scientific). Primers were 
designed to amplify a 1521 bp cDNA fragment from the end of exon 21 to the end of exon 25. PCR 
products were cloned into pCR-Blunt II-TOPO vector using Zero Blunt TOPO PCR Cloning Kit (Life 
Technologies). One Shot chemically competent E. coli cells were transformed with the pCR-Blunt 
II-TOPO construct. After selection with kanamycin, the constructs were Sanger sequenced using M13 
primers. 
DICER1 immunodetection 
Proteins were extracted from LCLs using RIPA lysis buffer (10 mM Tris–HCl pH 7.3, 10% sodium 
deoxycholate, 10% Triton X-100, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 10 mM beta-
glycerophosphate) supplemented with Complete, Mini, EDTA-free protease inhibitor cocktail 
(Roche). Western blot was performed using standard procedures and rabbit polyclonal anti-DICER1 
antibody (1:2000, A301-936A, Bethyl Laboratories, Inc., Montgomery, TX, USA) or mouse 
monoclonal anti-β-tubulin antibody, clone AA2 (1:1000, 05-661, Millipore Sigma). 
Results 
Clinical information 
At age 13 years, the proband (individual III-1 in pedigree, Fig. 1A) underwent right unilateral 
oophorectomy to remove an SLCT, and two years later, a total thyroidectomy was performed due to 
symptomatic non-toxic MNG. The elder of her two sisters underwent left unilateral oophorectomy at 
age 21 years due to an SLCT, and the other sister had a total thyroidectomy at age 13 years due to 
MNG (individuals III-3 and III-2, respectively). Several maternal relatives had a history of MNG. In 
addition, individual III-4 (proband’s cousin) had breast fibroadenoma and individual I-3 (proband’s 
grandfather) had MNG with a focus of differentiated thyroid cancer (Fig. 1A). Given that young-
onset MNG, alone or in combination with SLCT, is highly suggestive of DICER1 syndrome, genetic 
testing was undertaken. 
 
 
  
Figure 1. DICER1 screening results. (A) Family pedigree: carriers of the germline DICER1 in-frame deletion 
are indicated with ‘+’ and non-carriers with ‘−’. The arrowhead indicates the proband. SLCT, Sertoli-Leydig 
cell tumor; MNG, multinodular goiter; DTC, differenciated thyroid carcinoma. (B) Representation of MLPA 
results for non carrier (individual III-4) and a deletion carrier (III-1). A probe mix for DICER1 is used in 
combination with the P200-B1 set of control and reference probes from MRC-Holland (Amsterdam, The 
Netherlands). Both individuals are females; hence, the peak ratio value of 0 for the Y chromosome. No 
deletions or duplications in DICER1 were found in the non-carrier, with all ratios for DICER1exons (green 
squares, left) falling within the normal peak ratio range of 0.7–1.3 (green horizontal lines). Lower peak ratio 
values representing copy number loss were obtained for exons 23 and 24 in the deletion carriers (red arrow). 
Graphics generated with GeneMarker, v.1.70 (http://www.softgenetics.com/GeneMarker.html). (C) 
Chromatograms showing the somatic hotspot mutations found in tumors from DICER1deletion carriers. Panel 
1 shows the mutations identified in the proband’s (individual III-1) tumors. 1.a and 1.b show mutations found 
in different nodules from the MNG. 1.c shows the mutation found in the SLCT. Panel 2 shows the mutation in 
the MNG of the proband’s grandmother (individual I-4). Panel 3, mutation found in the MNG of the proband’s 
sister (individual III-2). Mutations are indicated by an asterisk.  
 
 
 
 
Germline and somatic mutation analyses 
Full sequencing of DICER1 in the proband’s germline DNA did not identify any point mutations or 
small insertions/deletions. However, MLPA showed copy loss for exons 23 and 24, corresponding to 
a deletion (Fig. 1B). Analysis of the DNA breakpoints identified a heterozygous germline in-
frame DICER1 deletion spanning 3901 bases (c.4207-41_5364+1034del) (Supplementary Fig. 1, see 
section on supplementary data given at the end of this article). It comprised 41 bases of the 3′ end of 
intron 22, exon 23, intron 23, exon 24 and 1034 bases of intron 24 (Fig. 2A panel I and Supplementary 
Fig. 1). 
 
  
Figure 2. Effect of DICER1 in-frame deletion on mRNA and at protein level. (A) Graphic representation of 
wild-type and mutant DICER1 DNA alleles (Panel I), and the corresponding spliced mRNA transcripts (Panel 
II). In Panel I, boxes represent exons, horizontal lines represent introns, red shading indicates the deleted region 
and the arrow indicates the first deleted base. (B) 1.5% agarose gel showing the results of PCR amplification 
of a cDNA fragment spanning from exon 21 to exon 25 (1521 bp). Given that the DNA deletion begins in 
intron 22 and ends in intron 24, following mRNA splicing, a product of 363 bp comprising exon 22 spliced to 
exon 25, and lacking exons 23 and 24, may be expected. This 363 bp product from the mutant allele, in addition 
to the 1521 bp product from the wild-type allele, were detected in mRNA from LCLs from individual III-3 
(proband’s sister) and individual II-2 (proband’s mother). Only the wild-type fragment was detected in a 
control sample (C). ‘L’ is the 100 bp DNA Ladder H3 RTU (GeneDireX, Ontario, Canada), and ‘B’ is a blank 
control PCR reaction. (C) Sequencing of PCR products obtained in B, showed a loss of exon 23 and 24 in the 
mutation carriers. (D) Western blot showing DICER1 and tubulin protein expression in carriers (individuals 
III-3 and II-2) and in a control (C). Wt, wild type. 
 
 
 
 
Testing of a further fifteen family members revealed eight additional carriers of the in-frame deletion, 
including the proband’s two sisters (individuals III-2 and III-3) and her mother (II-2) (Fig. 1A). All 
carriers had been diagnosed with MNG or SLCT (or both in the case of the proband), except for two 
individuals who were healthy as of September 2017 at ages 42 and 10 years (individuals II-7 and III-
6, respectively). Two non-carriers had MNG (individuals I-3 and II-8, diagnosed at age 70 and 28 
years respectively), one with a focus of differentiated thyroid cancer (DTC), papillary subtype. An 
additional female non-carrier was diagnosed with a breast fibroadenoma at 22 years of age (individual 
III-4). 
Screening for somatic DICER1 hotspot mutations was performed on 7 tumor samples from 6 
individuals. Two individual nodules from the proband’s MNG each harbored a distinct RNase IIIb 
hotspot mutation (c.5113G>C, p.E1705Q and c.5114A>T, p.E1705V; Fig. 1C, chromatograms 1.a 
and 1.b), and a c.5437G>C, p.E1813Q mutation was found in her SLCT (Fig. 1C, chromatogram 1.c). 
Two MNG samples from deletion carriers also had somatic RNase IIIb hotspot mutations (individual 
I-4 had c.5126A>G, p.D1709G, Fig. 1C, chromatogram 2; and individual III-2 had c.5429A>T, 
p.D1810V; Fig. 1C, chromatogram 3), although we did not find a somatic hotspot mutation in the 
MNG from individual II-2. The grandfather’s MNG (individual I-3) and the cousin’s breast 
fibroadenoma (individual III-4) did not have mutations in the sequence encoding the RNase IIIa or 
IIIb domains of DICER1 (data not shown). The latter two individuals were non-carriers of the familial 
mutation. 
Expression of the germline in-frame deletion transcript/protein 
PCR amplification of a region from exon 21 to exon 25 was performed on cDNA synthesized from 
germline RNA from control patients and deletion carriers. The full amplified region spanned 1521 
base pairs (Fig. 2A panel II). A band corresponding to a wild-type (wt) mRNA transcript (1521 bp) 
was present in control samples. However, in DICER1 deletion carriers, we identified two bands: one 
corresponding to the wt mRNA transcript and another corresponding to the mutant mRNA transcript 
(363 bp) (Fig. 2A and B). As the LCLs used for mRNA extraction were not treated with an inhibitor 
of nonsense-mediated decay (NMD), the PCR results indicate that the mutant transcript was not 
subjected to NMD (Fig. 2B). Sequencing of the PCR products confirmed that the mutant mRNA band 
(363 bp) lacked exons 23 and 24 (Fig. 2C). Carriers expressed a lower level of wt DICER1 protein 
compared to controls, as shown by Western blot (Fig. 2D). The mutant transcript is predicted to be 
translated into a shorter DICER1 protein of ~200 kDa, devoid of 107 of 165 amino acids constituting 
the RNase IIIb domain. However, this could not be proven as a protein of ~200 kDa was also observed 
in the control sample (Fig. 2D), possibly a naturally occurring alternate protein isoform. 
Discussion 
Hyperplastic thyroid abnormalities are a common finding in patients with 
germline DICER1 mutations (7), and risk of thyroid carcinoma in DICER1 syndrome patients is 
elevated (13, 16). The penetrance of heterozygous germline DICER1 pathogenic variants for 
neoplasia is seemingly low (<15%), although for some conditions such as MNG, it may be higher 
(6, 17, 18). Indeed, in a recent study by Khan and coworkers, by age 40 years, the cumulative 
incidence of MNG or thyroidectomy was observed to be 75% in women and 17% in men 
with DICER1 syndrome, compared to 8% and 0% of control women and men, respectively (13). 
In this study in which 8 relatives had MNG, we screened for DICER1 mutations using MLPA and 
unveiled a germline in-frame DICER1 deletion in nine family members. This emphasizes the 
effectiveness of MLPA in detecting single- or multiple-exon insertions and deletions, which would 
be missed by Sanger sequencing (15) and might also be overlooked by targeted, massively parallel, 
panel-based gene sequencing approaches. 
In our family, the deletion in DICER1 appears to be highly penetrant as seven of nine carriers (77%) 
had MNG, SLCT or both diseases. The remaining two carriers have no history of syndromic disease 
as of September 2017. Typical somatic hotspot mutations were found in three out of four carriers for 
whom tumor was available. The absence of a second hit in individual II-2 could be due to a lack of 
sensitivity of Sanger sequencing in detecting a low frequency variant. However, it is possible that 
individual II-2 does not have a somatic DICER1 mutation, as seen inthyroid nodules from some 
germline DICER1 mutation carriers (13). The two non-carriers with thyroid conditions (MNG and/or 
thyroid cancer) may suggest the involvement of different genetic or environmental factors. In fact, 
the region of Italy from which the family originates and resides has a high prevalence of MNG 
(19, 20). 
Studies of DICER1-associated tumors have revealed biallelic DICER1 mutations. The two-hit genetic 
model in DICER1 syndrome involves one germline typically truncating mutation (a nonsense or a 
frame-shift mutation) and a somatic missense mutation in the region encoding the RNase IIIb domain 
(Fig. 3). Germline mutations occur across the entire gene, whereas somatic mutations appear to be 
clustered at bases encoding the metal ion-binding or adjacent residues (p.E1705, p.D1709, p.D1810 
and p.E1813) of RNase IIIb domain, so-called ‘hotspots’ (7, 12, 21). This domain is crucial for the 
production of mature microRNAs from the 5p arm of precursor microRNAs (22). Amino acid 
substitutions at these hotspots interfere with the catalytic site of DICER1 leading to a 3p mature 
microRNA strand bias (22), which results in altered microRNA-mediated posttranscriptional gene 
regulation (23). 
 
 
 
 
 
 
Figure 3. Genetic models in DICER1 syndrome. Representations of the different genetic models found in 
patients with DICER1 syndrome in comparison to a healthy individual with two wild-type copies of DICER1. 
From top to bottom, we show a normal DICER1 genotype, the classic 2-hit model of DICER1 syndrome, the 
loss-of-heterozygosity model, the RNase IIIb mosaic model, PAZ/Platform missense model and the in-frame 
deletion described in this study. Relevant domains are highlighted in dark colors. Germline is shown in solid 
green, early mosaic in orange diamonds and somatic with blue stripes. White rectangles depict the four key 
amino acids (‘hotspots’) in RNase IIIb domain. 
Variations of this model have also been described (Fig. 3): (a) Germline truncating mutation 
accompanied by somatic loss of heterozygosity (LOH) has been frequently observed in 
pineoblastoma, (24) and has also been seen in a Wilms tumor (25) and a pituitary blastoma (14); (b) 
somatic mosaicism for an RNase IIIb hotspot mutation. In this case, the cells that give rise to a tumor 
acquire a truncating mutation as the second hit (26, 27). This scenario is associated with an early-
onset and severe multifocal phenotype compared to patients with the classical two-hit model (26); 
and (c) germline missense mutations in the region coding for the PAZ/platform domain accompanied 
by a somatic hotspot mutation (6, 28). Here, we suggest another model, wherein heterozygous loss of 
two relevant metal ion-binding residues (i.e. p.E1705 and p.D1709) in the germline appears to be 
sufficient to provoke DICER1 syndrome (Fig. 3). 
Five in-frame deletions in DICER1 have been previously published. Rio Frio and coworkers 
investigated two families with history of MNG, which resulted from in-frame deletions (6). One 
family was found to bear a missense mutation that created a de novo splice site, producing a transcript 
with an in-frame deletion of the first 21 base pairs of exon 16 (r.2437_2457del21, p.I813_Y819del). 
The other family had a splice site mutation (c.2805-1G>T) that resulted in an in-frame deletion of 
exon 18 (6). Both mutations altered the structure of DICER1 by eliminating part of the Platform or 
PAZ domains (Fig. 3). A similar case was presented by Yoshida and colleagues. They described a 
12-year-old girl diagnosed with anaplastic sarcoma of the kidney and follicular thyroid carcinoma 
who had a germline insertion/deletion in DICER1 (c.5426_5442delGGGATATTTTTGAGTC 
GinsCA, p.G1809_S1814delinsA). Although a small deletion, it resulted in DICER1 devoid of three 
key residues (p.G1809, p.D1810 and p.E1813) in the RNase IIIb domain (29). In the study by Rath 
and coworkers (10), they found a germline in-frame deletion (c.5221_5232delAACAACACCATC, 
p.N1741_I1744del) in a 9-year-old boy with cystic nephroma, MNG and pleuropulmonary blastoma 
(PPB). The father, who had been diagnosed with PPB and MNG, was also a carrier. Interestingly, the 
elimination of four amino acids in RNase IIIb domain, although not hotspot residues, was able to 
predispose to DICER1 syndrome. Finally, Doros and coworkers described a child with abdominal 
embryonal rhabdomyosarcoma bearing c.4259_4261delGAG (p.1418_1420delE). Based on the 
amino acid conservation and the location of the glutamic acid in an acidic portion of DICER1, they 
proposed that the change would be pathogenic (30) although no functional evidence was provided. In 
addition to these published cases, ClinVar lists two other in-frame deletions, 
c.3516_3525delTACAGCAATTinsA (p.T1173_I1175del), which is reported to be pathogenic by a 
single submitter, but with no supporting details (https://www.ncbi.nlm.nih.gov/clinvar/variation/ 
429158/), and c.4260_4262delGGA (p.E1420del), which has the same end-result at the protein level 
as the in-frame deletion described by Doros and coworkers (30), but in this case, it is reported to be 
likely benign by multiple submitters (https://www.ncbi.nlm.nih.gov/clinvar/variation/133971/). The 
in-frame deletion shown in our study, which spanned 3901 bases, is the largest 
intragenic DICER1 deletion described in the literature. 
In the thyroid gland, DICER1 and microRNAs are necessary for accurately establishing thyroid 
follicles and hormone synthesis. Normal thyroid highly expresses let-7 isoforms, miR-15/miR-16 
cluster and other miRNAs (31). Conversely, these microRNAs have been found to be downregulated 
in thyroid tumors (32). Using mouse models, the specific depletion of DICER in thyrocytes led to 
loss of follicular architecture, was associated with functional aberrations, caused downregulation of 
thyroid cell differentiation markers (33) and also led to induction of cell proliferation (34). Moreover, 
several microRNAs predicted to target the 3′-UTR of thyroid differentiation genes (e.g. NIS, 
TG or DUOX1) and thyroid transcription factors (e.g. PAX8, NKX2-1 and FOXE1) were found to be 
downregulated in Dicer1 knockout models (35). 
The development of MNG has been described to start with a goitrogenic stimulus such as an 
environmental factor (i.e. iodine deficiency) or a genetic alteration that causes diffuse thyroid 
hyperplasia. Then, an increase in the mutagenic load of the thyroid occurs either consequent to an 
increase in the H2O2 production and free radical formation due to thyroid hormone synthesis, or by a 
failure of mutation repair due to higher thyroid cell replication rate. Finally, some of the resulting cell 
clones will contain an advantageous mutation that causes growth of multiple thyroid nodules (2). 
In agreement with this, de Kock and coworkers proposed a model of DICER1-related MNG 
development in which a germline loss-of-function DICER1mutation creates a haploinsufficient 
environment leading to diffuse thyroid hyperplasia. Subsequently, the acquisition of an RNase IIIb 
mutation on the other allele results in the formation of a monoclonal nodule. Over time, more nodules 
appear as more RNase IIIb mutations occur in thyroid cells, ultimately resulting in MNG (12). 
In this study, we hypothesize that the loss of crucial amino acids in RNase IIIb due to the 
germline DICER1 in-frame deletion leads to a decreased production of 5p microRNAs, which result 
in thyroid cell proliferation. It has been shown that let-7a and miR-345 (both 5p microRNAs) are 
downregulated in DICER1-related goiter, compared to normal thyroid tissue (6). Moreover, low 
levels of let-7 and miR-345 have been recurrently found in thyroid tumors (32, 36). After the 
induction of hyperplasia, DICER1 ‘hotspot’ mutations in RNase IIIb may occur on the other allele 
(as observed in the proband, individual I-4 and individual III-2), giving rise to cell clones that would 
develop into thyroid nodules. 
Taken together, these results suggest that loss of one or more clusters of key residues (p.E1705 and 
p.D1709 and/or p.G1809, p.D1810 and p.E1813) in the domain involved in premature microRNA 
cleavage is enough to ‘lay the groundwork’ for DICER1 syndrome to occur, since in nearly all cases, 
the tumors occurring in DICER1 syndrome require a second hit in exons encoding the RNase IIIb 
domain, and conversely, nearly all of these somatic RNase IIIb hits occur in the context of an 
inactivating mutation on the other allele. In this study, we found a novel in-frame DICER1deletion, 
which resulted in a mutant transcript lacking exons 23 and 24. The resulting protein, if expressed in 
its entirety, would lack two metal ion-binding amino acids in the RNase IIIb domain, which are crucial 
for DICER1 catalytic activity. Therefore, in-frame germline mutations must be carefully analyzed 
when assessing their potential to cause DICER1 syndrome as they may eliminate bases encoding for 
physiologically critical amino acids. 
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